Evidence map›Paper›PMID 36287321›Full record

ArticleMycopathologia2023

Draft Genome Sequence of the Fluconazole-Resistant Candida palmioleophila Clinical Isolate CBS 18098.

Rose-Anne Lavergne, Paul Barbier, Lenha Mobuchon, Atanu Banerjee, Rajendra Prasad, Florent Morio

Abstract read
PubMed Publisher
In one paragraph

Article in Mycopathologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. First report of the emerging pathogenic yeastFrontiers in fungal biology · 2025
    Article
  3. The first rare case ofFrontiers in microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rose-Anne LavergneCHU de Nantes, Cibles et Médicaments des Infections et de l'Immunité, Nantes Université, IICiMed, UR1155, 44000, Nantes, France.ORCID http://orcid.org/0000-0001-9339-1562
Paul BarbierService de Virologie, CHU Nantes, 44000, Nantes, France.
Lenha MobuchonDépartement de Biologie, CHU Nantes, 44000, Nantes, France.ORCID http://orcid.org/0000-0003-4938-2460
Atanu BanerjeeAmity Institute of Biotechnology and Amity Institute of Integrative Sciences and Health, Amity University Haryana, Gurugram, India.ORCID http://orcid.org/0000-0001-9319-4593
Rajendra PrasadAmity Institute of Biotechnology and Amity Institute of Integrative Sciences and Health, Amity University Haryana, Gurugram, India.ORCID http://orcid.org/0000-0002-8044-7042
Florent MorioCHU de Nantes, Cibles et Médicaments des Infections et de l'Immunité, Nantes Université, IICiMed, UR1155, 44000, Nantes, France. florent.morio@chu-nantes.fr.ORCID http://orcid.org/0000-0002-5859-6105

Funding

Department of Biotechnology, Ministry of Science and Technology, India BT/PR32349/MED/29/1456/2019
6 · The paper itself

Abstract

Candida palmioleophila belongs to the Saccharomycetales. This opportunistic yeast which has been associated with invasive infections in human and animals, warrants a specific attention as it is frequently misidentified and display reduced susceptibility to fluconazole. Here, we report the first draft genome of C. palmioleophila, obtained from a clinical isolate.

Indexed as

CandidaFluconazoleAnimalsAntifungal AgentsDrug Resistance, FungalHumansMicrobial Sensitivity TestsSaccharomyces cerevisiaeAntifungal AgentsFluconazoleCandida palmioleophilaCBS 18098Draft genomeFluconazole resistanceOpportunistic yeast

Identifiers

PMID36287321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.